BMO Capital analyst Keith Tapper lowered the firm’s price target on Neurogene (NGNE) to $16 from $45 and keeps an Outperform rating on the ...

Neurogene (NGNE) announced a peer-reviewed publication on its EXACT transgene regulation technology. The preclinical ...

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Neurogene Inc. before investing. In this article, we go over a few key elements ...

Investing.com — Neurogene Inc. (NASDAQ: NGNE ), une entreprise pharmaceutique avec une capitalisation boursière de 163,48 millions $, a annoncé aujourd’hui une modification à un accord existant avec B ...

The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and ...

2025--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases ...

Neurogene has a 1-year low of $13.47 and a 1-year high of $74.49. Institutional Investors Weigh In On Neurogene Several large investors have recently made changes to their positions in NGNE.

NEUROGENE ($NGNE) is expected to release its quarterly earnings data on Monday, March 17th after market close, per Finnhub. Analysts are expecting revenue of $0 and ...

Investing.com — Lundi, BMO Capital Markets a ajusté ses perspectives sur Neurogene (NASDAQ: NGNE) en réduisant considérablement l’objectif de cours de la société de 45,00$ à 16,00$. Malgré ce changeme ...

NEW YORK - Neurogene Inc. (NASDAQ: NGNE), a clinical-stage biotech company currently valued at $156 million, has announced the publication of a study in Science Translational Medicine detailing its ...